Pancreatic Cancer Research

ResearcherChang Gung UniversityNo recent work listed

Tsann‐Long Hwang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8927-2384; OpenAlex author ID A5103468020, A5112259250. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers

Papers 12

  1. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which P… Co-author DOI 10.1016/j.ijrobp.2023.02.061↗
  2. Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance. Last author DOI 10.3390/ijms24087331↗
  3. The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm8122225↗
  4. Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical center. Last author DOI 10.1016/j.asjsur.2016.11.009↗
  5. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. Last author DOI 10.21873/invivo.11411↗
  6. Surgical Margin Status of Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Radical Intent: Risk Factors for the Survival Impact of Positi… Co-author DOI 10.21873/invivo.11419↗
  7. Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer. Last author DOI 10.1097/md.0000000000004191↗
  8. A novel role of the tumor size in pancreatic cancer as an ancillary factor for predicting resectability. Co-author DOI 10.4103/0973-1482.131464↗
  9. Pancreatic ductal adenocarcinoma presenting with acute and chronic pancreatitis as initial presentation: is prognosis better? A comparison study.. Last author PMID 25713917↗
  10. Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. Co-author DOI 10.1186/1477-7819-10-77↗
  11. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced… Co-author DOI 10.1016/j.ijrobp.2010.10.034↗
  12. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. Co-author DOI 10.1371/journal.pone.0020029↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chih-Po Hsu · 4 shared papers, 2016–2023 · strength 0.46
  2. Chun‐Nan Yeh · 6 shared papers, 2012–2018 · strength 0.38
  3. Yu-Chi Kuo · 1 shared paper, 2023 · strength 0.24
  4. Jen‐Shi Chen · 2 shared papers, 2011–2023 · strength 0.20
  5. Yen‐Feng Chiu · 2 shared papers, 2011–2023 · strength 0.20
  6. Li‐Tzong Chen · 2 shared papers, 2011–2023 · strength 0.20
  7. Hui-Ju Ch’ang · 2 shared papers, 2011–2023 · strength 0.20
  8. Yan‐Shen Shan · 2 shared papers, 2011–2023 · strength 0.20
  9. Chung‐Pin Li · 1 shared paper, 2023 · strength 0.18
  10. Kun‐Chun Chiang · 3 shared papers, 2012–2018 · strength 0.16
  11. Wey‐Ran Lin · 1 shared paper, 2019 · strength 0.09
  12. Chun‐Cheng Chiang · 1 shared paper, 2019 · strength 0.09
  13. Chun‐Chi Lai · 1 shared paper, 2018 · strength 0.09
  14. Miin‐Fu Chen · 2 shared papers, 2012–2014 · strength 0.08
  15. Keng-Hao Liu · 1 shared paper, 2016 · strength 0.06
  16. Shih-Chun Chang · 1 shared paper, 2016 · strength 0.06
  17. Ashok Thorat · 1 shared paper, 2014 · strength 0.06
  18. Jau‐Song Yu · 1 shared paper, 2011 · strength 0.02
  19. Ya‐Ting Chang · 1 shared paper, 2011 · strength 0.02
  20. Yu‐Wen Tien · 1 shared paper, 2011 · strength 0.02
  21. Ann‐Lii Cheng · 1 shared paper, 2011 · strength 0.02
  22. Ming‐Chu Chang · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.